CASE DISCUSSION
Chronic Myeloid Leukemia: Targeted Therapies and Monitoring
Presented by Dr. Ram GanjooViews
1,382
Credit Points
Learning Hours
CPD Points
CME Points
Courses Completed
Case Description
Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder driven by the BCR-ABL fusion gene, which produces an abnormal tyrosine kinase. The introduction of tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib has revolutionized CML treatment, transforming it into a...
Case Summary
- Chronic Myeloid Leukemia (CML) arises from myeloid progenitor cells due to a genetic translocation between chromosomes 9 and 22, forming the Philadelphia chromosome and the BCR-ABL1 oncogene. This leads to excessive cell proliferation and reduced apoptosis. While the incidence in Western data is 1.5-2 per lack, in India it's 0.8-2.2 per lack. CML is more common in males and the median age of diagnosis in India (35-40 years) is lower than in the West (55-65 years).
Speaker Profile
Dr. Ram Ganjoo
Senior Consultant Medicine & Clinical Haematology, Sarvodaya Medicentre, DelhiDisclosures
Assimilate requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.